(Q36268282)

13 August 2017

1 reference

title

Neuroinflammation: a potential therapeutic target (English)

1 reference

13 August 2017

0 references

2

D Martin Watterson

1 reference

13 August 2017

3

Linda J Van Eldik

1 reference

13 August 2017

Jeffrey M Craft

1

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 October 2005

1 reference

Expert Opinion on Therapeutic Targets

13 August 2017

published in

1 reference

13 August 2017

volume

9

1 reference

13 August 2017

issue

5

1 reference

13 August 2017

page(s)

887-900

1 reference

Interleukin-1, neuroinflammation, and Alzheimer's disease

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Polymorphisms in inflammatory genes and the risk of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Inflammation and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Inflammation and the degenerative diseases of aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Atypical inflammation in the central nervous system in prion disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Cellular pathology of Parkinson's disease: astrocytes, microglia and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Parkinson's disease and inflammatory changes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Clinical trial of indomethacin in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Indomethacin reverses the microglial response to amyloid beta-protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Comparison between flurbiprofen and its nitric oxide-releasing derivatives HCT-1026 and NCX-2216 on Abeta(1-42)-induced brain inflammation and neuronal damage in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Chronic neuroinflammation in rats reproduces components of the neurobiology of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

The effects of a novel NSAID on chronic neuroinflammation are age dependent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

2-Dialkylamino-6-acylmalononitrile substituted naphthalenes (DDNP analogs): novel diagnostic and therapeutic tools in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Nonsteroidal Anti-Inflammatory Drugs Can Lower Amyloidogenic Aß 42 by Inhibiting Rho

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Do NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Double placebo design in a prevention trial for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

The role of PPAR-gamma in macrophage differentiation and cholesterol uptake.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

The mechanisms of action of PPARs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Anti-inflammatory and antiproliferative actions of PPAR-gamma agonists on T lymphocytes derived from MS patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Hepatotoxicity with thiazolidinediones: is it a class effect?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Statins and the risk of dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Patients with Alzheimer's disease may be particularly susceptible to adverse effects of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Controversy surrounding the safety of cerivastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Clinically relevant differences between the statins: implications for therapeutic selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

NSAID and antioxidant prevention of Alzheimer's disease: lessons from in vitro and animal models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

The effects of Ginkgo biloba extract on lipopolysaccharide-induced inflammation in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Ginkgolide B inhibits the neurotoxicity of prions or amyloid-beta1-42

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Influence of the severity of cognitive impairment on the effect of the Gnkgo biloba extract EGb 761 in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

A double-blind, placebo-controlled, randomized trial of Ginkgo biloba extract EGb 761 in a sample of cognitively intact older adults: neuropsychological findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Ginkgo for memory enhancement: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Effects of melatonin on human mood and performance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Melatonin reverses the profibrillogenic activity of apolipoprotein E4 on the Alzheimer amyloid Abeta peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Antioxidants, oxidative stress, and degenerative neurological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Beta-amyloid precursor protein transgenic mice that harbor diffuse A beta deposits but do not form plaques show increased ischemic vulnerability: role of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Aminopyridazines inhibit beta-amyloid-induced glial activation and neuronal damage in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Discovery of a 3-amino-6-phenyl-pyridazine derivative as a new synthetic antineuroinflammatory compound

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Validation of the neuroinflammation cycle as a drug discovery target using integrative chemical biology and lead compound development with an Alzheimer's disease-related mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Ibuprofen: effect on inducible nitric oxide synthase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Inhibition of inducible nitric oxide synthase gene expression by indomethacin or ibuprofen in beta-amyloid protein-stimulated J774 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Statin therapy for Alzheimer's disease: will it work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Effects of lovastatin and pravastatin on amyloid processing and inflammatory response in TgCRND8 brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

Pravastatin at 10 mg/day does not decrease plasma levels of either amyloid-β (Aβ) 40 or Aβ 42 in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.9.5.887

21 January 2018

Identifiers

DOI

10.1517/14728222.9.5.887

1 reference

release_cribr3j3dzbptfo2zft7bwjjjq

13 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/cribr3j3dzbptfo2zft7bwjjjq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference